FAP-associated desmoid invasiveness correlates with in vitro resistance to doxorubicin

Familial Cancer

Volumn 8, Issue 4, 2009, Pages 569-580

  Joyner, David E ^a   Trang, Sylvia H ^a   Aboulafia, Albert J ^b   Damron, Timothy A ^c   Randall, R Lor ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Apoptosis related genes; Desmoid; Drug resistance; FAP; In vitro; Microarray; Motility

Indexed keywords

DOXORUBICIN; INTERSTITIAL COLLAGENASE; STROMELYSIN; TRYPAN BLUE;

ABDOMINAL WALL; ADENOMATOUS POLYP; APOPTOSIS; ARTICLE; ASSAY; BOYDEN CHAMBER ASSAY; CANCER INVASION; CELL CULTURE; CELL LINE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DESMOID TUMOR; DNA MICROARRAY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL ADENOMATOUS POLYPOSIS; FOXL2 GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NTN1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TNFRSF10C GENE; TUMOR CELL;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROMATOSIS, AGGRESSIVE; GENE EXPRESSION; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70449518027     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-009-9288-y     Document Type: Article

References (45)

1. BA Alman ME Pajerski S Diaz-Cano, et al. 1997 Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder Diagn Mol Pathol 6 98 101 10.1097/00019606-199704000-00005 1:STN:280:DyaK2s3ltlajtw%3D%3D 9098648 (Pubitemid 27155030)
2. F Angiero S Benedicenti M Stefani 2008 Fibromatosis of the head and neck: morphological, immunohistochemical and clinical features Anticancer Res 28 1725 1732 18630451
3. JS Biermann 2000 Desmoid tumors Curr Treat Options Oncol 1 262 266 10.1007/s11864-000-0038-5 1:STN:280:DC%2BD38zhsFSktw%3D%3D 12057169
4. AP Burke LH Sobin KM Shekitka 1990 Mesenteric fibromatosis. A follow-up study Arch Pathol Lab Med 114 832 835 1:STN:280:DyaK3czivVyjsA%3D%3D 2375657
5. S Cheng M Tada Y Hida, et al. 2008 High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma J Surg Res 146 104 109 10.1016/j.jss.2007.05.032 1:CAS:528: DC%2BD1cXksVaiu70%3D 17663001
6. S Cohen D Ad-El O Benjaminov, et al. 2008 Post-traumatic soft tissue tumors: case report and review of the literature a propos a post-traumatic paraspinal desmoid tumor World J Surg Oncol 6 28 10.1186/1477-7819-6-28 18312655
7. KM Debatin 1999 Activation of apoptosis pathways by anticancer drugs Adv Exp Med Biol 457 237 244 1:CAS:528:DC%2BD3cXis1Citrg%3D 10500798
8. F De Cian E Delay RC Rudigoz, et al. 1999 Desmoid tumor arising in a cesarean section scar during pregnancy: monitoring and management Gynecol Oncol 75 145 148 10.1006/gyno.1999.5539 10502442 (Pubitemid 29477818)
9. H Denys O De Wever B Nusgens, et al. 2004 Invasion and MMP expression profile in desmoid tumours Br J Cancer 90 1443 1449 10.1038/sj.bjc.6601661 1:CAS:528:DC%2BD2cXis1aitrs%3D 15054469 (Pubitemid 38590640)
10. MT Dimanche-Boitrel P Genne O Duchamp B Chauffert 1994 Confluence dependent resistance (CDR) to doxorubicin and E-cadherin expression in murine mammary cells Cancer Lett 85 171 176 10.1016/0304-3835(94)90271-2 1:CAS:528:DyaK2MXhtFKis7s%3D 7954333 (Pubitemid 24302956)
11. K Dobbin JH Shih R Simon 2003 Statistical design of reverse dye microarrays Bioinformatics 19 803 810 10.1093/bioinformatics/btg076 1:CAS:528:DC%2BD3sXjsVKmt7s%3D 12724289 (Pubitemid 36582395)
12. K Ezumi H Yamamoto I Takemasa, et al. 2008 Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case Jpn J Clin Oncol 38 222 226 10.1093/jjco/hyn004 18304951
13. T Fallen M Wilson B Morlan, et al. 2006 Desmoid tumors-a characterization of patients seen at Mayo Clinic 1976-1999 Fam Cancer 5 191 194 10.1007/s10689-005-5959-5 16736290 (Pubitemid 43824476)
14. Y Fang R Sullivan CH Graham 2007 Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity Exp Cell Res 313 866 877 10.1016/j.yexcr.2006.12.004 (Pubitemid 46273437)
15. T Ferenc J Sygut J Kopczyński, et al. 2006 Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background Pol J Pathol 57 5 15 16739877
16. J Fitamant C Guenebeaud MM Coissieux, et al. 2008 Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer Proc Natl Acad Sci USA 105 4850 4855 10.1073/pnas.0709810105 1:CAS:528:DC%2BD1cXkt12qtLw%3D 18353983 (Pubitemid 351753835)
17. V Gouazé ME Mirault S Carpentier R Salvayre T Levade N Andrieu-Abadie 2001 Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells Mol Pharmacol 60 488 496 11502879
18. HS Hosalkar JT Torbert EJ Fox, et al. 2008 Musculoskeletal desmoid tumors J Am Acad Orthop Surg 16 188 198 18390481
19. Y Jilong W Jian Z Xiaoyan, et al. 2007 Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis Pathology 39 319 325 10.1080/00313020701329823 17558858 (Pubitemid 46897606)
20. DE Joyner KH Albritton JD Bastar, et al. 2006 G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line J Orthop Res 24 474 480 10.1002/jor.20087 1:CAS:528:DC%2BD2sXlsV2jsL8%3D 16450387 (Pubitemid 43778359)
21. AL Knudsen S Bülow 2001 Desmoid tumour in familial adenomatous polyposis. A review of literature Fam Cancer 1 111 119 10.1023/A:1013841813544 1:STN:280:DC%2BD3svps1SnsQ%3D%3D 14574007
22. Y Kong R Poon P Nadesan, et al. 2004 Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis Cancer Res 64 5795 5803 10.1158/0008-5472.CAN-03-3112 1:CAS:528:DC%2BD2cXmslaksrk%3D 15313922 (Pubitemid 39099306)
23. D Kotiligam AJ Lazar RE Pollock, et al. 2008 Desmoid tumor: a disease opportune for molecular insights Histol Histopathol 23 117 126 1:CAS:528:DC%2BD1cXhtVKgtr4%3D 17952864
24. K Kudoh M Ramanna R Ravatn, et al. 2000 Monitoring the expression profiles of doxorubicin induced and doxorubicin-resistant cancer cells by cDNA microarray Cancer Res 60 4161 4166 1:CAS:528:DC%2BD3cXlvFOkt7g%3D 10945624
25. K Lee MD Pisarska JJ Ko, et al. 2005 Transcriptional factor FOXL2 interacts with DP103 and induces apoptosis Biochem Biophys Res Commun 336 876 881 10.1016/j.bbrc.2005.08.184 1:CAS:528:DC%2BD2MXhtVegtb%2FP 16153597 (Pubitemid 41338350)
26. A Leithner M Gapp K Leithner, et al. 2004 Margins in extra-abdominal desmoid tumors: a comparative analysis J Surg Oncol 86 152 156 10.1002/jso.20057 15170654 (Pubitemid 38720766)
27. M Lund-Johansen R Bjerkvig PA Humphrey, et al. 1990 Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro Cancer Res 50 6039 6044 1:CAS:528:DyaK3cXlvVGgtbs%3D 2393868
28. J Mace J Sybil Biermann V Sondak C McGinn C Hayes D Thomas L Baker 2002 Response of extraabdominal desmoid tumors to therapy with imatinib mesylate Cancer 95 2373 2379 10.1002/cncr.11029 1:CAS:528:DC%2BD38XpsFSitbk%3D 12436445 (Pubitemid 35351145)
29. WA Messersmith DJ Ahnen 2008 Targeting EGFR in colorectal cancer N Engl J Med 359 1834 1836 10.1056/NEJMe0806778 1:CAS:528:DC%2BD1cXht12nu7fJ 18946069
30. BG Mills A Frausto E Brien 2000 Cytokines associated with the pathophysiology of aggressive fibromatosis J Orthop Res 18 655 662 10.1002/jor.1100180419 1:CAS:528:DC%2BD3cXotVOmt7w%3D 11052503
31. RL Momparler M Karon SE Siegel, et al. 1976 Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells Cancer Res 36 2891 2895 1:STN:280:DyaE283gvVWqtw%3D%3D 1277199
32. C Muller G Laurent V Ling 1995 P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells J Cell Physiol 163 538 544 10.1002/jcp.1041630314 1:CAS:528:DyaK2MXlslOru70%3D 7775597
33. S Okuno 2006 The enigma of desmoid tumors Curr Treat Options Oncol 7 438 443 10.1007/s11864-006-0019-4 17032556 (Pubitemid 44697781)
34. A Pryczynicz K Guzińska-Ustymowicz A Kemona, et al. 2008 Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma Anticancer Res 28 1399 1404 18505086
35. SM Pulukuri JS Rao 2008 Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis Int J Oncol 32 757 765 1:CAS:528: DC%2BD1cXkslOitrw%3D 18360703
36. BA Rosenzweig PS Pine OE Domon, et al. 2004 Dye bias correction in dual-labeled cDNA microarray gene expression measurements Environ Health Perspect 112 480 487 1:CAS:528:DC%2BD2cXjvFOqsLc%3D 15033598
37. T Saito Y Oda K Kawaguchi, et al. 2002 Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction Lab Invest 82 97 103 1:CAS:528:DC%2BD38XhtV2ksb0%3D 11796830
38. NJ Sturt MC Gallagher P Bassett CR Philp KF Neale IP Tomlinson AR Silver RK Phillips 2004 Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation Gut 53 1832 1836 10.1136/gut.2004.042705 1:CAS:528:DC%2BD2cXhtFejtbvM 15542524 (Pubitemid 39556906)
39. NJ Sturt SK Clark 2006 Current ideas in desmoid tumours Fam Cancer 5 275 285 10.1007/s10689-005-5675-1 16998673 (Pubitemid 44453858)
40. S Tejpar G Michils H Denys, et al. 2005 Analysis of Wnt/Beta catenin signalling in desmoid tumors Acta Gastroenterol Belg 68 5 9 1:STN:280: DC%2BD2M7pvVyqsA%3D%3D 15832580
41. S Tejpar F Nollet C Li, et al. 1999 Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor) Oncogene 18 6615 6620 10.1038/sj.onc.1203041 1:CAS:528:DyaK1MXnvFyhsLk%3D 10597266
42. S Tolan JH Shanks MY Loh, et al. 2007 Fibromatosis: benign by name but not necessarily by nature Clin Oncol (R Coll Radiol) 19 319 326 1:STN:280:DC%2BD2szgtlCgsQ%3D%3D
43. S Wang EA Konorev S Kotamraju J Joseph S Kalivendi B Kalyanaraman 2004 Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways J Biol Chem 279 25535 25543 10.1074/jbc.M400944200 1:CAS:528:DC%2BD2cXksFygsbc%3D 15054096 (Pubitemid 38756813)
44. YD Wang F Yang WD Chen X Huang L Lai BM Forman W Huang 2008 Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo Mol Endocrinol 22 1622 1632 10.1210/me.2007-0527 1:CAS:528:DC%2BD1cXot1ehurs%3D 18436567 (Pubitemid 351920395)
45. XD Zhang T Nguyen WD Thomas, et al. 2000 Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types FEBS Lett 482 193 199 10.1016/S0014-5793(00)02042-1 1:CAS:528:DC%2BD3cXntF2qtrY%3D 11024459 (Pubitemid 30750537)